Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Liabilities and Shareholders Equity (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $49.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 16.39% year-over-year to $49.3 million, compared with a TTM value of $185.5 million through Sep 2025, down 14.97%, and an annual FY2024 reading of $44.9 million, up 67.31% over the prior year.
  • Liabilities and Shareholders Equity was $49.3 million for Q3 2025 at Fennec Pharmaceuticals, up from $44.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $69.2 million in Q1 2024 and bottomed at $15.6 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $35.5 million, with a median of $28.0 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity crashed 44.63% in 2022, then soared 224.95% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $26.0 million in 2021, then grew by 3.56% to $26.9 million in 2022, then dropped by 0.28% to $26.9 million in 2023, then skyrocketed by 67.31% to $44.9 million in 2024, then rose by 9.6% to $49.3 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for FENC at $49.3 million in Q3 2025, $44.9 million in Q2 2025, and $46.4 million in Q1 2025.